CJC-1295 vs Tesamorelin
Comparison of CJC-1295 (Moderate evidence) and Tesamorelin (High evidence).
Last updated: February 12, 2026
CJC-1295
Tesamorelin
Overview
CJC-1295 and Tesamorelin are both studied in the peptide research space.
CJC-1295: A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life.
Tesamorelin: An FDA-approved GHRH analog for reducing visceral fat in HIV-associated lipodystrophy.
Evidence Comparison
| Aspect | CJC-1295 | Tesamorelin |
|---|---|---|
| Evidence Level | Moderate | High |
| Human Studies | 4 | 35 |
| Preclinical Studies | 2 | 4 |
| Total Sources | 14 | 52 |
Key Differences
| Aspect | CJC-1295 | Tesamorelin |
|---|---|---|
| Category | Hormonal | Hormonal |
| Evidence Strength | Moderate | High |
| Total Sources | 14 | 52 |
| Human Studies | 4 | 35 |
Summary
- CJC-1295: Moderate evidence with 14 total sources (4 human)
- Tesamorelin: High evidence with 52 total sources (35 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.